Silo Pharma (NASDAQ: SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the company's common stock. The program allows purchases to be made on the open market, through privately negotiated transactions, or by other means, in compliance with Securities and Exchange Commission rules and applicable legal requirements. As of Nov. 13, 2025, the company reported 13,318,273 shares of common stock outstanding, according to its quarterly report for the period ended Sept. 30, 2025.
The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations. The program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion. This move is often interpreted by the market as a signal that management believes the stock is undervalued and can enhance shareholder value by reducing the number of shares outstanding.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
The repurchase program comes at a time when the company is advancing its pipeline and seeking to create value for shareholders. By reducing the share count, earnings per share could increase, potentially making the stock more attractive to investors. However, the success of the program will depend on the company's ability to execute its business strategy and achieve milestones in its drug development programs.
For more details on the announcement, visit the full press release at https://ibn.fm/gU3uZ. The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO.
